Real-World data may reveal how well tafasitamab fights Hard-to-Treat lymphoma

NCT ID NCT07709624

Ongoing Disease control Sponsor: TTY Biopharm Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at how well the drug tafasitamab works in adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatment. Researchers will collect real-world data from 50 patients who are not eligible for a stem cell transplant. The main goal is to see how many patients achieve a complete or partial response to the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tafasitamab
What this could lead to: If successful, this study could confirm tafasitamab's effectiveness in a broader, real-world population of DLBCL patients who cannot have a stem cell transplant.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by patient selection or other treatments. The small size (50 patients) limits how widely findings can be applied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DLBCL

Contacts and locations

Show contact details

Locations

Tty Biopharm

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.